Hopital Prive Jean Mermoz

The medical center is at the forefront of research in Non-Small Cell Lung Cancer, focusing on innovative maintenance therapies post-chemotherapy. The center's work aims to enhance the efficacy of treatments like pembrolizumab, offering new hope for patients with advanced stages of this disease.

• Maintenance therapies
• Immunotherapy advancements
• Personalized treatment approaches

Through rigorous clinical trials, the center is contributing to the development of personalized medicine strategies that could significantly improve patient outcomes.

Specializing in ER-positive and HER2-negative breast cancer, the center is pioneering studies on the efficacy of combination therapies involving durvalumab, olaparib, and fulvestrant. These efforts are crucial in advancing treatment options for patients with specific genetic profiles.

• Combination therapy efficacy
• Genetic profiling in treatment
• Progression-free survival improvements

The center's research is instrumental in tailoring therapies to individual genetic markers, potentially transforming the standard of care for breast cancer patients.

In the realm of pancreatic surgery, the center is exploring the use of intrapapillary botulinum toxin injections to prevent postoperative pancreatic fistulas. This innovative approach could lead to significant reductions in surgical complications.

• Postoperative complication reduction
• Innovative surgical techniques
• Botulinum toxin applications

By focusing on preventive measures, the center aims to enhance recovery and quality of life for patients undergoing pancreatic surgery.

The center is conducting pivotal research on locally advanced anal squamous cell carcinoma, comparing induction chemotherapy followed by chemoradiotherapy to standard treatments. This work is vital in improving survival rates and treatment efficacy.

• Induction chemotherapy strategies
• Comparative treatment efficacy
• Survival rate enhancement

Through these studies, the center is contributing to the optimization of treatment protocols for anal cancer, potentially setting new standards in oncological care.

Focusing on advanced biliary cancer, the center is evaluating maintenance treatments targeting actionable genetic mutations. This research is crucial for developing more effective, personalized treatment plans for patients with this challenging cancer type.

• Targeted maintenance therapies
• Genetic mutation targeting
• Personalized treatment development

The center's efforts are paving the way for more precise and effective interventions in biliary cancer, potentially improving patient survival and quality of life.